| ObjectiveMalignant ascites is one of the common complications in some tumors, and is a sign of disease progression and poor prognosis. Patients happen abdominal distention, magersucht and poor appetite, causing great pain to patients, not only lower the quality of life, and shorten the lifetime. There are so many methods to treatment, but the report that patients can be effectively controlled to malignant ascites and improved symptoms on the premise of the tolerance is not much. Anticancer Chinese medicine injections is research and development in recent decades, it besides has anti-cancer effect and also can improve the body’s immune function, improve patients’life quality, and have a litter of toxic and side reaction. Now Cinobufacini injection is one of the most explicit anticancer Chinese medicine injections, and joint hyperthemal perfusion therapy to treating malignant ascites. Through observing the clinical efficacy and the security index, possible mechanism of action is discussed. The treatment of malignant ascites may expand some new ways to provide beneficial information.MethodsThe case source of topic is from the patients, selectted and accorded with inclusion criteria of the topic, that had cancer with malignant ascites at the tumor medical ward of Hospitals of traditional Chinese and Western medicine of Guangdong province medical ward malignant tumor with malignant ascites in12/2012-12/2013. Grouped by random method, the two groups have25cases, respectivel. Cinobufacini injection group perfusate used10ml Cinobufacini injection multiply by10and100mg lidocaine and NS3000ml; The Nedaplatin group used90mg Nedaplatin and100mg lidocaine and NS3000ml. Two groups treat five days once, and three times were one course of treatment. Using the self-controlled study and controlled trials, observed the change of T-lymphocyte subsets, ascites quantity, ascites tumor markers and KPS to assess on clinical curative effect, and the security index to know the toxic and side effectResultSelf-controlled study of Cinobufacini injection group:1. Peritoneal effusion quantity of curative effect evaluation:all25patients, patients with complete remission,8cases,11cases were markedly improved,3cases ineffective in3, and the total effective rate was76%;2. The correlative clinical symptom integral evaluation:their comparison before and after treatment had significant differences p<0.01;3. KPS score curative effect evaluation:KPS score changes before and after treatment with significant difference (p<0.05);4. Ascites tumor markers in the level evaluation:CEA, CA125, CA153, CA199, before treatment and after treatment, there are significant differences (p <0.05).Controlled trials to the Cinobufacini injection group and the Nedaplatin group:1. In the two groups before and after treatment of T lymphocyte subgroup level assessment:treatment group CD3+, CD4+, CD4+/CD8+more significant differences before and after the treatment (p<0.05), and CD8+before and after treatment was no significant difference (p>0.05); Control group of CD3+, CD4+, CD8+, CD4+/CD8+before and after treatment was no significant difference (p>0.05); HuaChan group after treatment of CD3+, CD4+, CD4+/CD8+compared with Nedaplatin group after treatment had significant difference (p<0.05).2. Two groups of peritoneal effusion quantity of curative effect evaluation: all the50cases of patients, the treatment group and control group two groups of cases, the same two groups of peritoneal effusion quantity curative effect comparison there was no significant difference (p>0.05);3. Two groups of clinical symptoms integral evaluation:two groups of clinical symptoms integral comparison there was no significant difference (P>0.05);4. KPS score curative effect evaluation:the two groups was no significant difference between the two groups (p>0.05);5. In50cases of security index evaluation:two groups of adverse reaction in treatment is given priority to with pain, vomiting and diarrhea, two groups did not appear in the process of treatment as a result of the drug causes the changes of electrocardiogram (ecg); Liver and renal abnormalities and adverse reactions such as bone marrow suppression. Incidence of adverse reactions to contrast the two groups, including pain and diarrhea incidence of no significant difference (p>0.05); Vomiting incidence have significant difference (p<0.05).Conelusion1. Cinobufacini injection hyperthermic intraperitoneal therapy can significantly improve patients with late malignant tumor CD3+, CD4+, CD4+/CD8+cell proportion, thus improve the patients’immune function, inhibit the activity of tumor cells.2. Cinobufacini injection hyperthermic intraperitoneal therapy for malignant ascites had significantly lower levels of tumor markers in function, may be related to injection anticancer HuaChan element and heat effect to improve the activity and sensitivity;3. Cinobufacini injection hyperthermic intraperitoneal therapy to a certain extent, can inhibit the growth of malignant peritoneal effusion, overall efficiency>60%, the control effect is better.4. Cinobufacini injection hyperthermic intraperitoneal therapy improved significantly abdominal compression symptoms, the patients clinical symptoms eased, and KSP score also improved significantly;5. Cinobufacini injection local infusion, the patient’s medication, can significantly improve the "wet poison card";6. Cinobufacini injection hyperthermic intraperitoneal happen less adverse reaction, the patient tolerance is better, worthy of clinical promotion. |
PDF Full Text Request